US FDA approves viloxazine extended-release capsules for treatment of attention-deficit hyperactivity disorder (ADHD) in paediatric patients 6-17 years of age

Viloxazine is a novel non-stimulant for ADHD, acting as a norepinephrine reuptake inhibitor with selective serotonin modulation activity. Approval was based on data from four Phase III clinical trials including over 1000 paediatric patients.

Source:

Biospace Inc.